European Hematology Association Congress

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

Lydia Scarfò, MD, discusses long-term data with BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.

Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.

David Curtis, MBBS, PhD, FRACP, FRCPA, discusses the use of post-transplant cyclophosphamide GVHD prophylaxis in matched donor peripheral blood SCT.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.

ASC4START data support potential for asciminib to be standard of care for newly diagnosed chronic myeloid leukemia in chronic phase.

ESAs or danazol in combination with ruxolitinib displayed similar spleen and symptom outcomes in myelofibrosis with anemia.

Olutasidenib maintenance led to 83% 4-month RFS rate and 89% 12-month OS rate in IDH1-mutated AML.

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

A post hoc analysis of the PhALLCON study showed response and survival benefits with imatinib in Ph-positive ALL with MRD negativity after induction.

Oral iptacopan monotherapy led to hemoglobin level and transfusion independence benefits vs anti-C5 therapies in paroxysmal nocturnal hemoglobinuria.

Cyclosporin/cyclophosphamide after allogeneic stem cell transplant improved outcomes vs cyclosporin/methotrexate in high-risk hematologic malignancies.